Investigational drug · Phase 3
FRSW117
Also called: Recombinant human coagulation factor Ⅷ-Fc fusion protein
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Severe Hemophilia A.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "FRSW117"
First trial start
2023
Dec 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FRSW117", any sponsor or status.
Conditions studied
As listed on its trial records.
- Severe Hemophilia A
Approved drugs for the same conditions: Hemophilia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "FRSW117" as an intervention, largest first.
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinPivotal-lookingCompleted
Hangzhou Gensciences Biopharmaceutical Co., Ltd.Industry
NCT06142552 · 124 participants · Start Dec 27, 2023 · Primary completion Oct 8, 2025
Drug: FRSW117 · For: Severe Hemophilia A
Sites: Beijing, China; Changsha, China; Chongqing, China · 28 sites in all
Hangzhou Gensciences Biopharmaceutical Co., Ltd.Industry
NCT05265286 · 15 participants · Start Apr 14, 2022 · Primary completion Aug 21, 2022
Drug: FRSW117 · For: Severe Hemophilia A
Sites: Zhengzhou, China; Wuxi, China; Qingdao, China · 5 sites in all
Hangzhou Gensciences Biopharmaceutical Co., Ltd.Industry
NCT04864743 · 13 participants · Start Jun 22, 2021 · Primary completion Oct 17, 2021
Drug: ADVATE; FRSW117 · For: Severe Hemophilia A
Sites: Guangzhou, China; Zhengzhou, China; Jinan, China · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
Also in development for Severe Hemophilia A
- FRSW107Phase 33 trials
Hangzhou Gensciences Biopharmaceutical Co., Ltd. · Severe Hemophilia A
- GS1191-0445Phase 32 trials
Gritgen Therapeutics Co., Ltd. · Severe Hemophilia A, Hemophilia A
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.